Canada Approves Arrowhead’s REDEMPLO for Rare Triglyceride Disorder
Arrowhead Pharmaceuticals has received regulatory clearance from Health Canada for REDEMPLO (plozasiran), marking a significant advance for patients living with familial chylomicronemia syndrome (FCS), a rare and severe genetic disorder characterized by …